Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and 
II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG

Vazquez-Blomquist, Dania; Hardy-Sosa, Anette; Baez, Saiyet C.; Besada, Vladimir; Palomares, Sucel; Guirola, Osmany; Ramos, Yassel; Wiśniewski, Jacek R.; Javier Gonzalez, Luis; Bello-Rivero, Iraldo

doi:10.3390/cells11244068

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG

MPS-Authors

/persons/resource/persons78895

Wiśniewski, Jacek R.
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Vazquez-Blomquist, D., Hardy-Sosa, A., Baez, S. C., Besada, V., Palomares, S., Guirola, O., et al. (2022). Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG. Cells, 11(24): 4068. doi:10.3390/cells11244068.

Cite as: https://hdl.handle.net/21.11116/0000-000C-753F-B

Abstract

HeberFERON, a co-formulation of Interferon (IFN)-alpha 2b and IFN-gamma, has effects on skin cancer and other solid tumors. It has antiproliferative effects over glioblastoma multiform (GBM) clones and cultured cell lines, including U-87 MG. Here, we report the first label-free quantitative proteomic and phospho-proteomic analyses to evaluate changes induced by HeberFERON after 72 h incubation of U-87 MG that can explain the effect on cellular proliferation. LC-MS/MS, functional enrichment and networking analysis were performed. We identified 7627 proteins; 122 and 211 were down- and up-regulated by HeberFERON (fold change > 2; p < 0.05), respectively. We identified 23,549 peptides (5692 proteins) and 8900 phospho-peptides; 523 of these phospho-peptides (359 proteins) were differentially modified. Proteomic enrichment showed IFN signaling and its control, direct and indirect antiviral mechanisms were the main modulated processes. Phospho-proteome enrichment displayed the cell cycle as one of the most commonly targeted events together with cytoskeleton organization; translation/RNA splicing, autophagy and DNA repair, as represented biological processes. There is a high interconnection of phosphoproteins in a molecular network; mTOR occupies a centric hub with interactions with translation machinery, cytoskeleton and autophagy components. Novel phosphosites and others with unknown biological functionality in key players in the aforementioned processes were regulated by HeberFERON and involved CDK and ERK kinases. These findings open new experimental hypotheses regarding HeberFERON action. The results obtained contribute to a better understanding of HeberFERON effector mechanisms in the context of GBM treatment.